SITE015-0102

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-06-19

AEs

Serious

Dropout signal

–

Adverse events

severe assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 22); relationship: N

mild assessed

Grade 1 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-08-11 (study day 34); relationship: not assessed

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-12 (study day 35); relationship: not assessed

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-08-15 (study day 38); relationship: not assessed

mild assessed

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-14 (study day 68); relationship: not assessed

Data queries

No data queries.